H. van Onzenoort

First name
H.
Middle name
A.
Last name
van Onzenoort
Driessen, J. H., van Onzenoort, H. A., Henry, R. M., Lalmohamed, A. ., van den Bergh, J. P., Neef, C. ., … de Vries, F. . (2014). Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture. Bone. http://doi.org/10.1016/j.bone.2014.07.030
Pouwels, S. ., de Boer, A. ., Leufkens, H. G., Weber, W. E., Cooper, C. ., van Onzenoort, H. A., & de Vries, F. . (2014). Risk of fracture in patients with muscular dystrophies. Osteoporos Int. http://doi.org/10.1007/s00198-013-2442-2
Driessen, J. H., Henry, R. M., van Onzenoort, H. A., Lalmohamed, A. ., Burden, A. M., Prieto-Alhambra, D. ., … de Vries, F. . (2015). Bone fracture risk is not associated with the use of glucagon-like peptide-1 receptor agonists: a population-based cohort analysis. Calcif Tissue Int. http://doi.org/10.1007/s00223-015-9993-5
Driessen, J. H., van den Bergh, J. P., van Onzenoort, H. A., Henry, R. M., Leufkens, H. G., & de Vries, F. . (2017). Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: A retrospective population-based cohort study. Diabetes Obes Metab. http://doi.org/10.1111/dom.12843